NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

NeWBrO, Your reference is to Astrozenica's expansion in Maryland, so it can't apply to the UK facility.
But it could apply to NWBO's choice of a "company" in the US under the US manufacturing section of the10Q
I was just about to post this, so I'll do it in response to your post.

From the 10Q:

Manufacturing in the US – DCVax Products and Kalinski aDC1 Products.
The Company has been pursuing separate parallel tracks to develop manufacturing in the US of the Company’s DCVax-L products and of the aDC1 products pursuant to the technologies of Dr. Kalinski that the Company has in-licensed. For the production of DCVax-L products, during the first quarter the Company completed the selection of a US company, contract negotiations and entered into a technology transfer agreement for development of DCVax-L manufacturing capacity by the US company. The Standard Operating Procedures (SOPs) used in the UK are being adapted to the US facilities and operations, and training began during the first quarter. The Company anticipates that the required engineering runs and validations will be completed during the summer.

So again, we see a referene to NWBO choosing a separate company to work with manufacturing DCVax-L, this time in the US. It looks like they are already well ahead. Training personnel began in the first quarter of 2026 and they expect engineering runs and validations to be completed this summer.

I should note that manufacturing will likely start as compassionate care, which means patients will have to pay for treatment. It also means that the facility can only be in a state that has passed a law allowing compassionate care by drugs not approved yet by the FDA.

By contrast, NWBO says

For the production of Kalinski aDC1 products, the Company is working primarily to develop its own GMP manufacturing operation in the US, although it is also in discussions with a contractor for such production as an alternative. The Company has been in ongoing negotiations since last year to secure lease arrangements for a suitable GMP facility. In the meantime, during the first quarter the Company completed the lengthy recruitment process and hired the key manager to lead the aDC1 manufacturing operations.